SkinBioTherapeutics plc (AIM:SBTX)

Market Cap	43.35M
Revenue (ttm)	2.68M
Net Income (ttm)	-2.58M
Shares Out	258.78M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,348
Average Volume	976,058
Open	16.78
Previous Close	16.75
Day's Range	16.75 - 17.00
52-Week Range	9.00 - 27.50
Beta	0.74
RSI	50.63
Earnings Date	Dec 2, 2025

About Chimerix

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 15
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SBTX

Financial Performance

In 2024, SkinBioTherapeutics's revenue was 1.21 million, an increase of 815.26% compared to the previous year's 132,057. Losses were -2.88 million, 1.44% more than in 2023.